Quantcast
Home > Quotes > SNSS
SNSS

Sunesis Pharmaceuticals, Inc. Common Stock (SNSS) Quote & Summary Data

$1.25
*  
0.29
30.21%
Get SNSS Alerts
*Delayed - data as of Mar. 22, 2019  -  Find a broker to begin trading SNSS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
6
Today's High / Low
$ 1.27 / $ 0.926
Share Volume
3,918,443
50 Day Avg. Daily Volume
774,238
Previous Close
$ 0.96
52 Week High / Low
$ 3.49 / $ 0.20
Market Cap
84,472,609
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.9

Intraday Chart

Shares Traded

Share Volume:
3,918,443
50 Day Avg. Daily Volume:
774,238

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.75

Trading Range

The current last sale of $1.25 is 525.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.27 $ 3.49
 Low: $ 0.926 $ 0.20

Company Description (as filed with the SEC)

Sunesis Pharmaceutical, Inc. ("Sunesis" or the "Company") is a biopharmaceutical company focused on the development of new targeted inhibitors for the treatment of solid and hematologic cancers. Our primary activities since incorporation have been conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials, and raising capital. Our lead program is vecabrutinib, a non-covalent inhibitor of Bruton's Tyrosine Kinase, or BTK. In clinical trials, vecabrutinib has shown activity against both wild type and C481S-mutated BTK, the most common mutation associated with resistance to ibrutinib. Vecabrutinib is being studied in a Phase 1b/2 clinical trial to assess safety and activity in patients with advanced B-cell malignancies after two or more prior therapies, including ibrutinib or another covalent BTK inhibitor where approved for the disease.  ... More ...  



Risk Grade

Where does SNSS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.96
Open Date:
Mar. 22, 2019
Close Price:
$ 1.25
Close Date:
Mar. 22, 2019


Consensus Recommendation

Analyst Info